Edition:
United States

Merus NV (MRUS.OQ)

MRUS.OQ on NASDAQ Stock Exchange Global Market

17.49USD
20 Apr 2018
Change (% chg)

$0.38 (+2.22%)
Prev Close
$17.11
Open
$16.99
Day's High
$17.50
Day's Low
$16.96
Volume
5,934
Avg. Vol
10,364
52-wk High
$23.50
52-wk Low
$13.33

Latest Key Developments (Source: Significant Developments)

Merus And Vall d'Hebron Institute Of Oncology Announce Research Collaboration
Tuesday, 20 Mar 2018 07:00am EDT 

March 20 (Reuters) - Merus Nv ::MERUS AND VALL D'HEBRON INSTITUTE OF ONCOLOGY ANNOUNCE RESEARCH COLLABORATION TO DEVELOP INNOVATIVE BISPECIFIC ANTIBODIES FOR THERAPEUTIC APPLICATIONS IN TREATMENT OF CANCER.  Full Article

Merus Says Ono Pharma Exercised Option For New Research And License Agreement
Wednesday, 14 Mar 2018 07:00am EDT 

March 14 (Reuters) - Merus Nv ::MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES.MERUS NV - ‍ONO HAS AGREED TO FUND RESEARCH ACTIVITIES AT MERUS THAT WILL GENERATE CANDIDATE BICLONICS FOR NEW PROGRAM​.MERUS NV - ‍MERUS GRANTED ONO WORLDWIDE EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE RESULTING PRODUCTS DEVELOPED THROUGH COLLABORATION​.  Full Article

Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Simcere Pharmaceutical Group ::MERUS AND SIMCERE ANNOUNCE STRATEGIC COLLABORATION ON MULTIPLE BISPECIFIC ANTIBODIES.MERUS - AGREED TO GRANT SIMCERE EXCLUSIVE LICENSE TO DEVELOP & COMMERCIALIZE IN CHINA 3 BISPECIFIC ANTIBODIES USING CO'S BICLONICS TECHNOLOGY PLATFORM.MERUS NV- CO TO BE ELIGIBLE TO GET UPFRONT & MILESTONE PAYMENTS CONTINGENT UPON SIMCERE ACHIEVING CERTAIN SPECIFIED DEVELOPMENT & COMMERCIAL GOALS.MERUS NV - MERUS WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OF ANY PRODUCTS RESULTING FROM COLLABORATION IN CHINA FROM SIMCERE.MERUS NV - SIMCERE WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OUTSIDE OF CHINA FROM MERUS.MERUS NV - ADDITIONAL FINANCIAL DETAILS WERE NOT DISCLOSED UNDER COLLABORATION WITH SIMCERE.  Full Article

Merus Nv Q3 Loss Per Share Eur 0.81
Thursday, 30 Nov 2017 07:00am EST 

Merus Nv ::MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS.Q3 LOSS PER SHARE EUR 0.81.Q3 REVENUE EUR 3.5 MILLION VERSUS EUR 1.2 MILLION.Q3 REVENUE VIEW EUR 2.2 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW EUR -0.58 -- THOMSON REUTERS I/B/E/S.- ‍EXPECTS CURRENT CASH AND CASH EQUIVALENTS BALANCE TO BE SUFFICIENT TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS WELL INTO 2019​.  Full Article

Merus announces Q2 loss per share EUR 1.12
Tuesday, 19 Sep 2017 04:05pm EDT 

Sept 19 (Reuters) - Merus NV :Merus announces second quarter 2017 financial results and highlights recent progress.Q2 loss per share EUR 1.12.Q2 revenue EUR 4.0 million versus EUR 1.1 million.Q2 revenue view eur 2.2 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view EUR -0.52 -- Thomson Reuters I/B/E/S.Merus NV - Expects that current cash and cash equivalents balance will be sufficient to fund research and development programs, operations well into 2019.  Full Article

Merus Q1 loss per share EUR 1.15
Tuesday, 11 Jul 2017 04:05pm EDT 

July 11 (Reuters) - Merus Nv ::Merus announces first quarter 2017 financial results and mid-year operating results.Q1 loss per share EUR 1.15.Q1 revenue EUR 2.3 million versus EUR 800,000.Q1 revenue view EUR 42.8 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view EUR 1.55 -- Thomson Reuters I/B/E/S.Merus nv says by end of 2017, Merus expects to file a CTA for a first-in-human clinical trial of mcla-158 in patients with colorectal cancer.  Full Article

Merus reports Q4 loss per share eur 1.91
Friday, 28 Apr 2017 04:48pm EDT 

April 28 (Reuters) - Merus Nv -:Merus announces fourth quarter and full year 2016 financial results and corporate developments.Q4 loss per share eur 1.91.Q4 revenue eur 1.1 million versus eur 400,000.Q4 earnings per share view eur -0.52 -- Thomson Reuters I/B/E/S.Q4 revenue view eur 701090.00 -- Thomson Reuters I/B/E/S.  Full Article

Johnson & Johnson reports 7.4 pct stake in Merus NV as of Dec 31, 2016
Wednesday, 18 Jan 2017 05:59pm EST 

Johnson & Johnson :Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31, 2016 - SEC filing.  Full Article

Incyte and Merus announce global strategic research collaboration
Wednesday, 21 Dec 2016 07:00am EST 

Incyte Corp : Incyte and Merus announce global strategic research collaboration to discover and develop bispecific antibodies . Incyte to make up-front payment of $120 million and purchase $80 million of Merus common shares . Merus eligible to receive potential development, regulatory and commercial milestones and sales royalties . Parties have agreed to collaborate on development and commercialization of up to 11 bispecific antibody programs . Merus will retain all rights to develop and commercialize approved products in united states . Merus also has option to co-fund development of product candidates arising from two other programs . Incyte - for eight programs merus to be eligible to get potential development, regulatory and sales milestone payments of up to $350 million per program . Incyte will develop and commercialize approved products arising from program outside united states . For eight programs Incyte has agreed to independently fund all development and commercialization activities .Merus also eligible to receive tiered royalties ranging from 6 to 10 percent on global sales of approved products under 8 programs.  Full Article

Merus NV Q2 loss per share EUR 0.40
Monday, 8 Aug 2016 07:00am EDT 

Merus Nv : Q2 loss per share eur 0.40 . Q2 earnings per share view eur -0.49 -- Thomson Reuters I/B/E/S . Merus announces second quarter 2016 financial results and reviews recent clinical progress and corporate developments .Q2 revenue eur 1.1 million versus eur 1.2 million.  Full Article

BRIEF-Merus And Vall d'Hebron Institute Of Oncology Announce Research Collaboration

* MERUS AND VALL D'HEBRON INSTITUTE OF ONCOLOGY ANNOUNCE RESEARCH COLLABORATION TO DEVELOP INNOVATIVE BISPECIFIC ANTIBODIES FOR THERAPEUTIC APPLICATIONS IN TREATMENT OF CANCER Source text for Eikon: Further company coverage: